GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX 2,049.00
-27.00 (-1.30%)
Apr 24, 2026, 10:18 AM GMT
GSK plc Employees
GSK plc had 66,841 employees as of December 31, 2025. The number of employees decreased by 1,788 or -2.61% compared to the previous year.
Employees
66,841
Change (1Y)
-1,788
Growth (1Y)
-2.61%
Revenue / Employee
488.73K GBP
Profits / Employee
85.52K GBP
Market Cap
82.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66,841 | -1,788 | -2.61% |
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 96,100 |
| Haleon | 24,535 |
| Smith & Nephew | 16,988 |
| Convatec Group | 10,910 |
| Hikma Pharmaceuticals | 9,400 |
| CVS Group | 9,000 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,796 |
GSK plc News
- 2 hours ago - Top FTSE 100 shares to watch next week: Lloyds, Barclays, GSK, Natwest - Invezz
- 23 hours ago - FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings - Invezz
- 3 days ago - GSK Secures Approval for Blenrep in China for Multiple Myeloma Treatment - GuruFocus
- 10 days ago - GSK Reports Promising Phase I Results for Novel Cancer Treatment - GuruFocus
- 10 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer - Benzinga
- 10 days ago - GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% - GuruFocus
- 10 days ago - GSK Reports Promising Early Data For Experimental Cancer Drug - Benzinga
- 11 days ago - GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer - Nasdaq